Osteotropic effects by the neuropeptides calcitonin gene-related peptide, substance P and vasoactive intestinal peptide.
暂无分享,去创建一个
[1] T. Martin,et al. Principles of Bone Biology, 3rd ed. , 2009, American Journal of Neuroradiology.
[2] U. Lerner,et al. Expression of the calcitonin receptor, calcitonin receptor‐like receptor, and receptor activity modifying proteins during osteoclast differentiation , 2008, Journal of cellular biochemistry.
[3] L. Dai,et al. Changes of substance P-immunoreactive nerve fiber innervation density in the sublesional bones in young growing rats at an early stage after spinal cord injury , 2008, Osteoporosis International.
[4] U. Lerner,et al. Calcitonin inhibits osteoclast formation in mouse haematopoetic cells independently of transcriptional regulation by receptor activator of NF-{kappa}B and c-Fms. , 2007, The Journal of endocrinology.
[5] L. Dai,et al. Substance P and its receptors in bone metabolism , 2007, Neuropeptides.
[6] A. Stark,et al. Site‐specific CGRP innervation coincides with bone formation during fracture healing and modeling: A study in rat angulated tibia , 2007, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
[7] M. McKee,et al. Endocrine Regulation of Energy Metabolism by the Skeleton , 2007, Cell.
[8] G. Saxler,,et al. Polyethylene Particle-Induced Bone Resorption in Substance P-Deficient Mice , 2007, Calcified Tissue International.
[9] T. Goto,et al. Substance P stimulates late-stage rat osteoblastic bone formation through neurokinin-1 receptors , 2007, Neuropeptides.
[10] M. Palkovits,et al. Attenuated pseudorabies virus-evoked rapid innate immune response in the rat brain , 2006, Journal of Neuroimmunology.
[11] C. Kovacs,et al. Calcitonin plays a critical role in regulating skeletal mineral metabolism during lactation. , 2006, Endocrinology.
[12] K. Rabe,et al. Novel concepts of neuropeptide-based drug therapy: vasoactive intestinal polypeptide and its receptors. , 2006, European journal of pharmacology.
[13] U. Lerner,et al. Increased expression of interleukin-6 by vasoactive intestinal peptide is associated with regulation of CREB, AP-1 and C/EBP, but not NF-kappaB, in mouse calvarial osteoblasts. , 2005, Bone.
[14] U. Lerner,et al. The neuropeptide VIP potentiates IL-6 production induced by proinflammatory osteotropic cytokines in calvarial osteoblasts and the osteoblastic cell line MC3T3-E1. , 2005, Biochemical and biophysical research communications.
[15] C. Martínez,et al. Protective effect of vasoactive intestinal peptide on bone destruction in the collagen-induced arthritis model of rheumatoid arthritis , 2005, Arthritis research & therapy.
[16] 又吉 誉章. Neuropeptide substance P stimulates the formation of osteoclasts via synovial fibroblastic cells , 2005 .
[17] Masaki Noda,et al. Leptin regulation of bone resorption by the sympathetic nervous system and CART , 2005, Nature.
[18] S. Sohn. Substance P upregulates osteoclastogenesis by activating nuclear factor kappa B in osteoclast precursors , 2005, Acta oto-laryngologica.
[19] N. Hanai,et al. Osteoclast-like cells express receptor activity modifying protein 2: application of laser capture microdissection. , 2005, Journal of molecular endocrinology.
[20] I. Gozes,et al. Clinical endocrinology and metabolism. Potential clinical applications of vasoactive intestinal peptide: a selected update. , 2004, Best practice & research. Clinical endocrinology & metabolism.
[21] R. Emeson,et al. Decreased Bone Formation and Osteopenia in Mice Lacking α‐Calcitonin Gene‐Related Peptide , 2004 .
[22] T. Guo,et al. Capsaicin‐Sensitive Sensory Neurons Contribute to the Maintenance of Trabecular Bone Integrity , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[23] M. de Vernejoul,et al. RAMPs and CRLR expressions in osteoblastic cells after dexamethasone treatment. , 2004, Biochemical and biophysical research communications.
[24] R. Lefebvre,et al. Interaction of NO and VIP in gastrointestinal smooth muscle relaxation. , 2004, Current pharmaceutical design.
[25] T. Nagata,et al. Substance P enhances the inhibition of osteoblastic cell differentiation induced by lipopolysaccharide from Porphyromonas gingivalis. , 2004, Journal of periodontology.
[26] D. Pozo,et al. The Significance of Vasoactive Intestinal Peptide in Immunomodulation , 2004, Pharmacological Reviews.
[27] C. Laplace,et al. Amylin inhibits bone resorption while the calcitonin receptor controls bone formation in vivo , 2004, The Journal of cell biology.
[28] Darrell R. Abernethy,et al. International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.
[29] A. Bradley,et al. Increased bone mass is an unexpected phenotype associated with deletion of the calcitonin gene. , 2002, The Journal of clinical investigation.
[30] E. Goetzl,et al. Immunoeffector and immunoregulatory activities of vasoactive intestinal peptide , 2002, Regulatory Peptides.
[31] Patricia Ducy,et al. Leptin Regulates Bone Formation via the Sympathetic Nervous System , 2002, Cell.
[32] A. Couvineau,et al. Molecular pharmacology and structure of VPAC Receptors for VIP and PACAP , 2002, Regulatory Peptides.
[33] Y. Matsusue,et al. Neuronal regulation of bone metabolism and anabolism: Calcitonin gene‐related peptide‐, substance P‐, and tyrosine hydroxylase‐containing nerves and the bone , 2002, Microscopy research and technique.
[34] Teruo Tanaka,et al. Tachykinins and tachykinin receptors in bone , 2002, Microscopy research and technique.
[35] Patrick M. Sexton,et al. International Union of Pharmacology. XXXII. The Mammalian Calcitonin Gene-Related Peptides, Adrenomedullin, Amylin, and Calcitonin Receptors , 2002, Pharmacological Reviews.
[36] G. Thomas,et al. Hypothalamic Y2 receptors regulate bone formation. , 2002, The Journal of clinical investigation.
[37] I. Reid,et al. Effects of calcitonin, amylin, and calcitonin gene-related peptide on osteoclast development. , 2001, Bone.
[38] Z. Dąbrowski,et al. Effect of the neuropeptide substance P on the rat bone marrow‐derived osteogenic cells in vitro , 2001, Journal of cellular biochemistry.
[39] J. Fahrenkrug. Gut/brain peptides in the genital tract: VIP and PACAP , 2001, Scandinavian journal of clinical and laboratory investigation. Supplementum.
[40] H. Cooke. Neurotransmitters in Neuronal Reflexes Regulating Intestinal Secretion , 2000, Annals of the New York Academy of Sciences.
[41] M. Pondel,et al. Calcitonin and calcitonin receptors: bone and beyond , 2000, International journal of experimental pathology.
[42] P. Lehenkari,et al. Vasoactive intestinal peptide regulates osteoclast activity via specific binding sites on both osteoclasts and osteoblasts. , 2000, Bone.
[43] Shiaoping C. Zhu,et al. A Glia-Derived Signal Regulating Neuronal Differentiation , 2000, The Journal of Neuroscience.
[44] U. Lerner,et al. Microisolated mouse osteoclasts express VIP-1 and PACAP receptors. , 2000, Biochemical and biophysical research communications.
[45] H. Taniguchi,et al. The inhibitory effects of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide on osteoclast formation are associated with upregulation of osteoprotegerin and downregulation of RANKL and RANK. , 2000, Biochemical and biophysical research communications.
[46] P. Bergmann,et al. Effects of CGRP on human osteoclast-like cell formation: a possible connection with the bone loss in neurological disorders?☆ , 2000, Peptides.
[47] Arndt F Schilling,et al. Leptin Inhibits Bone Formation through a Hypothalamic Relay A Central Control of Bone Mass , 2000, Cell.
[48] I. Gozes,et al. Vasoactive Intestinal Peptide: Link between Electrical Activity and Glia‐mediated Neurotrophism , 1999, Annals of the New York Academy of Sciences.
[49] K. Smans,et al. Neuro-hormonal control of bone metabolism: vasoactive intestinal peptide stimulates alkaline phosphatase activity and mRNA expression in mouse calvarial osteoblasts as well as calcium accumulation mineralized bone nodules , 1999, Regulatory Peptides.
[50] K. Kataoka,et al. Substance P regulates the function of rabbit cultured osteoclast; increase of intracellular free calcium concentration and enhancement of bone resorption. , 1999, Biochemical and biophysical research communications.
[51] I. Reid,et al. Comparison of the Effects of Calcitonin Gene‐Related Peptide and Amylin on Osteoblasts , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[52] R. Flavell,et al. Targeted Expression of Calcitonin Gene‐Related Peptide to Osteoblasts Increases Bone Density in Mice , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[53] T. Tanaka,et al. Light- and electron-microscopic study of the distribution of axons containing substance P and the localization of neurokinin-1 receptor in bone , 1998, Cell and Tissue Research.
[54] C. Shih,et al. Neurogenic Substance P Stimulates Osteogenesis In Vitro , 1997, Peptides.
[55] T. Nagatsu,et al. Expression of mRNAs for neuropeptide receptors and β-adrenergic receptors in human osteoblasts and human osteogenic sarcoma cells , 1997, Neuroscience Letters.
[56] K. Matsumoto,et al. Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) stimulate interleukin-6 production through the third subtype of PACAP/VIP receptor in rat bone marrow-derived stromal cells. , 1997, Endocrinology.
[57] E. Greenfield,et al. Stimulation by Parathyroid Hormone of Interleukin-6 and Leukemia Inhibitory Factor Expression in Osteoblasts Is an Immediate-early Gene Response Induced by cAMP Signal Transduction (*) , 1996, The Journal of Biological Chemistry.
[58] C. Kovacs,et al. Pituitary adenylate cyclase-activating peptide stimulates cyclic AMP accumulation in UMR 106 osteoblast-like cells. , 1996, The Journal of endocrinology.
[59] R. Chole,et al. A mechanism for sympathectomy-induced bone resorption in the middle ear. , 1995, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.
[60] T. Bonner,et al. Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. , 1994, Endocrinology.
[61] M. Ransjö,et al. Helodermin, helospectin, and PACAP stimulate cyclic AMP formation in intact bone, isolated osteoblasts, and osteoblastic cell lines , 1994, Calcified Tissue International.
[62] I. Owan,et al. The role of calcitonin gene-related peptide (CGRP) in macrophages: the presence of functional receptors and effects on proliferation and differentiation into osteoclast-like cells. , 1994, Bone and mineral.
[63] S. Goldring,et al. Receptors for secretin, calcitonin, parathyroid hormone (PTH)/PTH-related peptide, vasoactive intestinal peptide, glucagonlike peptide 1, growth hormone-releasing hormone, and glucagon belong to a newly discovered G-protein-linked receptor family , 1993, Trends in Endocrinology & Metabolism.
[64] S. Santavirta,et al. Rapid proliferation of calcitonin gene-related peptide-immunoreactive nerves during healing of rat tibial fracture suggests neural involvement in bone growth and remodelling , 1993, Neuroscience.
[65] M. Zaidi,et al. Amylin inhibits bone resorption by a direct effect on the motility of rat osteoclasts , 1993, Experimental physiology.
[66] I. Owan,et al. Mechanism of action of amylin in bone , 1992, Journal of cellular physiology.
[67] M. Schultzberg,et al. Neuroendocrine regulation of cyclic AMP formation in osteoblastic cell lines (UMR‐106–01, ROS 17/2.8, MC3T3‐E1, and Saos‐2) and primary bone cells , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[68] T. Martin,et al. Structure‐activity relationships in calcitonin gene‐related peptide: Cyclic AMP response in a preosteoblast cell line (ks‐4) , 1991, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[69] M. Zaidi,et al. Selective antagonism of calcitonin-induced osteoclastic quiescence (Q effect) by human calcitonin gene-related peptide-(Val8Phe37). , 1991, Biochemical and biophysical research communications.
[70] R. Elde,et al. Distribution of CGRP-, VIP-, DβH-, SP-, and NPY-immunoreactive nerves in the periosteum of the rat , 1991, Cell and Tissue Research.
[71] T. Martin,et al. Effects of calcitonin gene‐related peptide on cyclic AMP formation in chicken, rat, and mouse bone cells , 1989, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[72] L. Terenius,et al. Neuropeptide Y-, tyrosine hydroxylase- and vasoactive intestinal polypeptide-immunoreactive nerves in bone and surrounding tissues. , 1988, Journal of the autonomic nervous system.
[73] M. Schultzberg,et al. Substance P- and CGRP-immunoreactive nerves in bone , 1988, Peptides.
[74] G. Mundy,et al. Human synthetic calcitonin gene-related peptide inhibits bone resorption in vitro. , 1986, Endocrinology.
[75] K. Torizuka,et al. Human calcitonin gene-related peptide possesses weak inhibitory potency of bone resorptionin vitro , 1986, Calcified Tissue International.
[76] E. Hohmann,et al. Innervation of periosteum and bone by sympathetic vasoactive intestinal peptide-containing nerve fibers. , 1986, Science.
[77] T. Martin,et al. Calcitonin gene-related peptide (CGRP) acts independently of calcitonin on cyclic AMP formation in clonal osteogenic sarcoma cells (UMR 106-01) , 1986, Calcified Tissue International.
[78] G. Roodman,et al. 1,25-Dihydroxyvitamin D3 causes formation of multinucleated cells with several osteoclast characteristics in cultures of primate marrow. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[79] H. Morris,et al. The myotropic and plasma-calcium modulating effects of calcitonin gene-related peptide (CGRP) , 1984, Neuropeptides.
[80] L. McManus,et al. Identification and characterization of osteoclast-like cells and their progenitors in cultures of feline marrow mononuclear cells , 1984, The Journal of cell biology.
[81] E. Hohmann,et al. Functional receptors for vasoactive intestinal peptide on human osteosarcoma cells. , 1984, Endocrinology.
[82] E. Hohmann,et al. Vasoactive intestinal peptide stimulates bone resorption via a cyclic adenosine 3',5'-monophosphate-dependent mechanism. , 1983, Endocrinology.
[83] R. Rosenberg,et al. Vasoactive intestinal polypeptide: abundant immunoreactivity in neural cell lines and normal nervous tissue. , 1976, Science.
[84] V. Mutt,et al. Structure of the Porcine Vasoactive Intestinal Octacosapeptide , 1974 .
[85] S. Said,et al. Biological activities of synthetic peptides corresponding to fragments of and to the entire sequence of the vasoactive intestinal peptide. , 1973, Proceedings of the National Academy of Sciences of the United States of America.
[86] V. Mutt,et al. Isolation from porcine-intestinal wall of a vasoactive octacosapeptide related to secretin and to glucagon. , 1972, European journal of biochemistry.
[87] V. Mutt,et al. Polypeptide with Broad Biological Activity: Isolation from Small Intestine , 1970, Science.
[88] V. Mutt,et al. Long Acting Vasodilator Peptide from Lung Tissue , 1969, Nature.
[89] U. Lerner,et al. Kinins and Neuro-osteogenic Factors , 2008 .
[90] U. Lerner. Deletions of genes encoding calcitonin/alpha-CGRP, amylin and calcitonin receptor have given new and unexpected insights into the function of calcitonin receptors and calcitonin receptor-like receptors in bone. , 2006, Journal of musculoskeletal & neuronal interactions.
[91] R. Henning,et al. Vasoactive intestinal peptide: cardiovascular effects. , 2001, Cardiovascular research.
[92] P. Lehenkari,et al. Vasoactive intestinal peptide (VIP)/pituitary adenylate cyclase-activating peptide receptor subtypes in mouse calvarial osteoblasts: presence of VIP-2 receptors and differentiation-induced expression of VIP-1 receptors. , 2001, Endocrinology.
[93] Vasoactive intestinal peptide prevents experimental arthritis , 2001 .
[94] P. Lehenkari,et al. Vasoactive Intestinal Peptide (VIP)/Pituitary Adenylate Cyclase-Activating Peptide Receptor Subtypes in Mouse Calvarial Osteoblasts: Presence of VIP-2 Receptors and Differentiation-Induced Expression of VIP-1 Receptors * * The present study was supported by grants from the Swedish Medical Research C , 2001, Endocrinology.
[95] A. Kreicbergs,et al. Sensory nerves in the interface membrane of aseptic loose hip prostheses. , 1998, The Journal of bone and joint surgery. British volume.
[96] O. Kozawa,et al. Pituitary adenylate cyclase-activating polypeptide induces cAMP production independently from vasoactive intestinal polypeptide in osteoblast-like cells. , 1994, Cellular signalling.
[97] 純也 鹿志村. Pituitary adenylate cyclase activating polypeptide(PACAP)のラット膵外分泌機能に対する作用 : ラット遊離膵腺房における,PACAPの作用,その作用機序,結合部位に関する検討 , 1994 .
[98] Y. Oiso,et al. Pituitary adenylate cyclase-actviating polypeptide induces cAMP production independently from vasoactive intestinal polypeptide in osteoblast-like cells , 1994 .
[99] M. Zaidi,et al. Further studies on the mode of action of calcitonin on isolated rat osteoclasts: pharmacological evidence for a second site mediating intracellular Ca2+ mobilization and cell retraction. , 1993, The Journal of endocrinology.
[100] S. Santavirta,et al. Distribution of nerve endings and sensory neuropeptides in rat synovium, meniscus and bone. , 1992, International journal of tissue reactions.
[101] B. Roos,et al. Evaluation of the in vivo and in vitro calcium-regulating actions of noncalcitonin peptides produced via calcitonin gene expression. , 1986, Endocrinology.
[102] V. Mutt,et al. Structure of the porcine vasoactive intestinal octacosapeptide. The amino-acid sequence. Use of kallikrein in its determination. , 1974, European journal of biochemistry.